🇮🇳·13h agoIndustry
intimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2
Publisher
N
Natco Pharma
India
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Natco Pharma
- Region
- India
- Scope
- Industry
- Published
- July 13, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on natcopharma.co.in
Leave the platform to read the original full article on the publisher site.
Source: Natco Pharma
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/2h ago
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
GSK News/6h ago
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Santen Pharmaceutical/13h ago
Santen and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%
Otsuka Holdings RSS/13h ago